NGF Program

NGF Program (sml)The discovery of Nerve Growth Factor (NGF) in the early 1950s by Rita Levi-Montalcini represents, without doubt, a breakthrough in the field of developmental neurobiology.

Thanks to the work of Rita Levi-Montalcini, NGF is  the most visible identity card of EBRI.

Moreover, the overall picture emerging from recent studies on NGF biology have led to the awareness of several pathological situations, in which the positive or negative modulation of NGF activity and signalling may have significant therapeutical benefits. The potential of developing new treatments for Alzheimer’s disease, based on NGF, is just the most significant example, while applications in the ophtalmological field having already undergone clinical testing.

EBRI is focusing on pursuing these therapeutical applications and, for this reason,  has set up a “NGF Program”, oriented towards research on NGF, based on the classical neuroembryological experiments of Rita Levi Montalcini on NGF in the chick embryo, and towards the development of therapeutical applications of NGF in human diseases.

The objectives of the NGF program are:

  1. to accelerate ongoing research in the field of neurotrophins by various research groups;
  2. to establish new collaborations and initiate new research lines in the NGF field;
  3. to facilitate dissemination of new knowledge and approaches in the NGF field;
  4. to promote collaborations with biotech and pharmaceutical industries, to support important therapeutic implications based on NGF.

EBRI  aims at establishing close collaborations with other external laboratories, scientists, clinician and biotech companies, so as to accelerate the clinical therapeutical applications of NGF and neurotrophins and transfer the knowledge from laboratories to clinical applications, for the benefit of society. A success in accelerating the development of therapeutical applications of NGF would represent for EBRI a major achievement, alongside its basic research programs.